NCT04628078 LAAC-registry: Clinical Outcome After Echocardiography-guided LAA-closure
| NCT ID | NCT04628078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2015-08-12 |
| Primary Completion | 2023-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2015-08-12 with a primary completion date of 2023-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims at comparing, in a large cohort of consecutive clinically indicated left atrial appendage closure, clinical and imaging outcomes between different subpopulations.
Eligibility Criteria
Inclusion Criteria: * Age\> 18 * Written informed consent to participate in the study * Patients with paroxysmal, persistent, or permanent non-valvular AF and CHA2DS2-VASc Score of ≥2 that are planned for an elective LAA-closure * Anatomic characteristics allow placement of a CE marked device, dedicated for LAAC Exclusion Criteria: * None. Considering the nature of the project, which is to prospectively collect information on all patients treated with LAAC in our center, we will only exclude patients unwilling to sign the informed consent.
Contact & Investigator
Lorenz Räber, Prof.
PRINCIPAL INVESTIGATOR
Insel Gruppe AG, Inselspital, Universitätsklinik für Kardiologie
Frequently Asked Questions
Who can join the NCT04628078 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04628078 currently recruiting?
Yes, NCT04628078 is actively recruiting participants. Contact the research team at lorenz.raeber@insel.ch for enrollment information.
Where is the NCT04628078 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT04628078 clinical trial?
NCT04628078 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Lorenz Räber, Prof. at Insel Gruppe AG, Inselspital, Universitätsklinik für Kardiologie. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.